No Placebo-Only Group

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have ovarian, fallopian tube, or peritoneal cancer.

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Monoclonal Antibody Therapy for Ovarian Cancer

This study is evaluating whether a monoclonal antibody can be used to treat ovarian, fallopian tube, or peritoneal cancer.

It's been over 4 weeks since my last platinum-based chemotherapy, and I'm not on any chemotherapy now.

My treatment plan does not specify endocrine therapy.

I haven't had whole abdomen radiotherapy and it's been 6+ months since my last limited area radiotherapy.

It has been over 4 weeks since my last surgery and I have not had my spleen removed.

I have had only one platinum-based chemotherapy treatment.

My blood pressure is controlled, and I don't have heart failure or irregular heartbeats.

My condition has not come back after treatment.

My cancer originates from the ovary, fallopian tube, or peritoneum.

My cancer is invasive and not considered low-grade.

My bilirubin levels are not more than 1.5 times the normal range.

I have never received mouse-derived antibody treatments.

I haven't taken any immunosuppressive or investigational drugs in the last 4 weeks.

I am able to get out of my bed or chair and move around.

Monoclonal Antibody Therapy

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tetanus toxoid may make tumor cells more sensitive to chemotherapy and vaccine therapy.

PURPOSE: Randomized phase II trial to study the effectiveness of chemotherapy and vaccine therapy with or without tetanus toxoid compared with chemotherapy alone in treating patients who have metastatic colorectal cancer.

Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer

Vaccine + Chemotherapy for Colorectal Cancer

This study is evaluating whether chemotherapy and vaccine therapy with or without tetanus toxoid might be more effective than chemotherapy alone in treating patients with metastatic colorectal cancer.

I am fully active or can carry out light work.

I do not have HIV, autoimmune diseases, allergies to egg or neomycin, and no bad reactions to tetanus vaccines.

I haven't had radiotherapy on more than half of my lymph nodes and no current radiotherapy affecting my bone marrow.

My lung condition is under control and not worsening.

My liver function tests are within the required limits and I don't have liver cirrhosis.

My cancer is a type of colorectal cancer that has spread.

I don't have ongoing major bowel issues or chronic diarrhea.

I have not had CEA-targeted immunotherapy or any other immunotherapy at the same time.

I haven't had a major organ transplant and have recovered from any previous surgeries.

It's been over 6 months since my last chemotherapy for early-stage cancer, and I haven't had chemo for advanced cancer.

I am not taking daily steroids or hormone therapy that isn't for replacement.

My heart condition is stable with no uncontrolled issues.

Chemotherapy

Tetanus Toxoid

Vaccine Therapy

The purpose of this study was to determine if an idiotype vaccine, made from a patient's lymphoma that has returned after chemotherapy and/or rituximab, would be able to shrink their tumor.

Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

Idiotype Vaccine for Non-Hodgkin's Lymphoma

This study is evaluating whether an idiotype vaccine can shrink a patient's tumor.

I have a history of lymphoma in my brain or its coverings.

My cancer has not worsened after my last treatment and has been stable or improved for at least 90 days.

My condition worsened within 3 months after my last cancer treatment.

I am currently on high-dose steroids or other immunosuppressive therapy.

I have had more than 3 prior treatments for my condition.

I am able to care for myself and perform daily activities.

My lymphoma is a type called grade 1 or 2 follicular B-cell.

I have received a vaccine designed to target my cancer.

I have been treated with fludarabine before.

I haven't had cancer surgery, radiotherapy, steroids, immunotherapy, or chemotherapy in the last 90 days.

I have been in remission for over 2 years from cancer, except for skin or cervical cancers.

Idiotype Vaccine

The purpose of the study is to determine whether T900607-sodium is effective and safe in treating hepatocellular carcinoma, a type of liver cancer.

Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.

T900607-Sodium for Liver Cancer

This study is evaluating whether a drug called T900607-sodium is effective and safe in treating hepatocellular carcinoma, a type of liver cancer.

I have severe heart issues, including weak heart pumping or chest pain.

I have not had any cancer other than skin cancer or cervical carcinoma in situ in the past 5 years.

I have had cancer spread to my brain or its coverings.

I've had treatments for liver cancer but it's been over 6 weeks since, and I have a new or growing tumor.

My liver cancer diagnosis was confirmed through tissue examination.

I have not had chemotherapy or radiotherapy for my liver cancer.

I am able to care for myself but cannot do normal activities or work.

I have a tumor that can be seen and measured on a CT scan.

I have not had major surgery in the last 4 weeks.

My liver function is classified as either good or moderately good.

T900607-Sodium

Pivotal Trial

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Vaccine Therapy for Patients With Stage III Melanoma

Vaccine Therapy for Stage III Melanoma

This study is evaluating whether a vaccine can prevent or slow the recurrence of melanoma.

All visible signs of my disease have been surgically removed.

I am not on medications or therapies that weaken my immune system.

CancerVax™ Vaccine

All Individual Drugs Already Approved

Approved for 10 Other Conditions

RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer

This study is evaluating whether ovarian function suppression with either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

My cancer has spread to distant parts of my body.

I have had cancer before, but it fits the exceptions.

My breast cancer was confirmed by a biopsy and is hormone receptor positive.

I became postmenopausal after surgery or chemotherapy.

I have noticeable cancer remaining in my underarm area.

I have had breast cancer before, either in the same or the other breast.

I have had surgery to remove both ovaries or radiation treatment on my ovaries.

I am not pregnant or breastfeeding and do not plan to become pregnant in the next 5 years.

I plan to use hormonal therapy in addition to the study treatment for the next five years.

I have been on hormone therapy for my breast cancer for over 8 months.

I was on tamoxifen or similar hormone therapy within a year before my breast cancer diagnosis.

I have received hormone therapy for breast cancer before being considered for this trial.

My estrogen levels are in the premenopausal range.

I haven't had chemotherapy and it's been less than 12 weeks since my surgery.

I finished my chemotherapy less than 8 months ago.

My cancer is only in my breast and nearby lymph nodes, with no spread elsewhere.

My breast cancer cannot be removed with surgery.

I have had surgery to remove lymph nodes or a biopsy showing no cancer in them.

I had surgery for breast cancer and no remaining signs of cancer in the area.

Exemestane

Oophorectomy

Tamoxifen

Triptorelin

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer.

PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Chemotherapy for Breast Cancer

This study is evaluating whether a combination of drugs is more effective than a single drug in treating breast cancer.

I have had surgery to remove breast cancer and affected lymph nodes.

I haven't had cancer in the past 5 years, except for certain skin cancers or early-stage cervical or breast cancer.

My cancer is at an early or mid-stage and can be operated on.

I know my cancer's estrogen and progesterone receptor status.

My tumor is smaller than 1 cm and doesn't meet certain criteria.

I have breast cancer in both breasts, diagnosed within a month of each other, and the more advanced tumor meets the study criteria.

My breast cancer is confirmed and not spread beyond stage III.

My tumor is larger than 2 cm or larger than 1 cm with specific features.

My cancer has not spread to my lymph nodes and my tumor is at least 1 cm with high-risk features or larger than 2 cm.

My cancer has not spread to nearby tissues.

My breast cancer has not spread to underarm or breast nodes.

My breast cancer has spread to my lymph nodes.

Cyclophosphamide

Doxorubicin Hydrochloride

Paclitaxel

RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment.

PURPOSE: This phase II trial is studying how well ^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

PET Imaging for Lung Cancer

This study is evaluating whether a PET scan can help doctors predict a patient's response to treatment and plan more effective treatment.

I am scheduled for combined chemotherapy and radiation treatment.

I don't plan to use biologic therapy for more than 14 weeks after my radiotherapy ends.

I don't plan to have chemotherapy for more than 14 weeks after finishing radiotherapy.

My lung cancer is confirmed to be non-small cell type.

My cancer has not spread to distant parts of my body.

My lung cancer is not the diffuse bronchoalveolar type.

I have not had radiation therapy to the chest area.

I am not currently undergoing intensity-modulated radiotherapy.

I am fully active or restricted in physically strenuous activity but can do light work.

I have received radiotherapy of 60 Gy or more and platinum-based chemotherapy at the same time.

I haven't had any cancer in the last 3 years, except for skin cancer or early-stage cancer that hasn't spread.

I am not scheduled for surgery to remove my cancer.

I am medically fit for intensive chemoradiotherapy.

I am currently receiving or can receive standard lung cancer treatment alongside another cancer study.

Chemoradiotherapy

Fludeoxyglucose F18 Positron Emission Tomography Imaging

This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

Lenalidomide + Dexamethasone +/- Thalidomide for Multiple Myeloma

This study is evaluating whether lenalidomide and low-dose dexamethasone works better than lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma.

I have had cancer before but meet specific conditions for this trial.

I do not have any serious illnesses that are not under control.

I have never had deep vein thrombosis or a pulmonary embolism.

I do not have severe numbness or pain in my hands or feet.

I was diagnosed with multiple myeloma recently and have symptoms.

My kidney and liver functions are within normal ranges.

I have had radiation therapy for symptom relief or targeted treatment.

I am following the required pregnancy prevention measures.

I have only used bisphosphonates for my multiple myeloma.

I do not have smoldering myeloma or MGUS.

I have not taken steroids for multiple myeloma.

I do not have any ongoing, untreated infections.

Dexamethasone

Lenalidomide

Thalidomide

This randomized phase III trial studies lenalidomide to see how well it works compared to a placebo in treating patients with multiple myeloma who are undergoing autologous stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Giving lenalidomide after autologous stem cell transplant may be an effective treatment for multiple myeloma.

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Lenalidomide for Multiple Myeloma

This study is evaluating whether lenalidomide might be an effective treatment for multiple myeloma.

My lungs work well enough to breathe without symptoms.

My multiple myeloma is active and needs treatment, and I've responded to initial therapy.

I started my first cancer treatment less than a year ago.

I have collected the required number of stem cells for my treatment.

My cancer did not worsen after my first treatment, and I've had no more than two treatment plans.

I am not pregnant or nursing and will follow strict birth control measures if of childbearing age.

I have not had any blood, bone marrow, or organ transplant.

I do not have any serious infections right now.

My heart pumps well, with an ejection fraction of 40% or higher.

I have had less than a year of treatment, including specific medications.

This randomized phase III trial studies oxaliplatin, leucovorin calcium, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin calcium, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer.

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Chemotherapy +/− Bevacizumab for Stage II Colon Cancer

This study is evaluating whether a combination of chemotherapy and bevacizumab is more effective than chemotherapy alone in treating patients who have undergone surgery for stage II colon cancer.

I have had a condition where my lymphocytes multiply unusually.

I haven't had any cancer except for skin cancer in the last 5 years.

I have a tumor sample available for specific genetic testing.

I have not had a heart attack or unstable angina in the last year.

I have symptoms related to poor blood flow in my limbs.

I do not have more than one tumor at the same time.

My lab tests for Step 2 were done within the last 2 weeks.

I have not had a stroke or mini-stroke in the last year.

I do not have symptoms from peripheral vascular disease.

My cancer has spread to the mesentery but without clear lymph node involvement.

I have had radiation therapy to my pelvic area before.

I haven't had significant bleeding unrelated to my colon cancer in the last 6 months.

I have a serious or non-healing wound, skin ulcer, or bone fracture.

I am currently experiencing significant nerve pain or tingling.

I have not had any major surgeries or procedures recently.

My tumor is located at least 12 cm from the anal opening, as confirmed by a doctor.

My colon cancer is confirmed to be Stage II adenocarcinoma.

I have hereditary non-polyposis colorectal cancer.

I have never had inflammatory bowel disease.

Fox Chase Cancer Center Clinical Trials 2022

Trials at this site